The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Dacopafant     8-pyridin-3-yl-7-thia-1...

Synonyms: CHEMBL67588, AG-H-81484, SureCN9376223, AC1L3TJS, RP-48740, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of RP 55778

  • The suppressive effects of RP 55778 on HIV expression appeared to be independent of the platelet-activating factor cell surface receptor on U1 cells [1].
  • No effect of RP 55778 was observed in MDM cultures infected with the primary isolate HIV-1/THI, whose replication is independent of TNF-alpha production and therefore remained unchanged after RP 55778 treatment [2].
  • The pretreatment with the specific PAF-acether receptor antagonist, BN 52021 (2.5-15 mg/kg), 48740 RP (6-25 mg/kg) and WEB 2086 (0.25-1 mg/kg) blocked the thrombocytopenia dose dependently [3].
  • N 48740 RP, a pyrrolo(1,2-c)thiazole derivative and platelet-activating factor inhibitor, was tested in a thrombosis model, in which thrombi are produced in small rat mesenteric vessels [4].
  • These results indicate that PAF and TNF can mediate the functional manifestations associated with endotoxemia and only RP 55778 appears to show potential for activity against an already established LPS response [5].
 

High impact information on RP 55778

  • RP 55778 inhibited acute HIV replication in primary T-cell blasts and the proliferative capacity of these cells [1].
  • Four different PAF-receptor antagonists belonging to four different series, CV-3988 (PAF-related framework), BN52021 (a natural terpenoid), BN53013 (a natural lignan) and 48740 RP (a synthetic antagonist) prevent the alteration induced by PAF [6].
  • RP 55778, a TNF-alpha synthesis inhibitor, decreases HIV replication in monocytes/macrophages [7].
  • The pharmacokinetic study of CsA showed that this lack of efficacy of combined treatment may be interpreted as the decreased CsA bioavailability observed when the animals also received RP 48740 [8].
  • The release of platelets induced by PAF was inhibited dose-dependently by specific PAF receptor antagonist such as WEB 2086 (0.5-2 mg/kg), BN 52021 and 48740 RP (5-25 mg/kg) [9].
 

Biological context of RP 55778

 

Associations of RP 55778 with other chemical compounds

 

Gene context of RP 55778

  • To investigate the relationship between TNF-alpha and viral replication we used a TNF-alpha synthesis inhibitor, RP 55778 [2].
  • Pretreatment of MDM with a TNF alpha synthesis inhibitor, RP 55778, 4 h prior to HIV infection induced a modified cytokine pattern during the first ten hours of infection: TNF alpha production was totally inhibited despite comparable amounts of IL6 [13].
  • Thus, in order to explore a possible link between these two factors, the effects of a PAF receptor antagonist, RP 55778, and a glucocorticoid, dexamethasone, were studied on LPS-induced hemoconcentration in rats and on the release of TNF induced by exposing isolated murine macrophages to LPS [5].
 

Analytical, diagnostic and therapeutic context of RP 55778

References

  1. A platelet-activating factor antagonist, RP 55778, inhibits cytokine-dependent induction of human immunodeficiency virus expression in chronically infected promonocytic cells. Weissman, D., Poli, G., Bousseau, A., Fauci, A.S. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed]
  2. Infection of human macrophages with an endogenous tumour necrosis factor-alpha (TNF-alpha)-independent human immunodeficiency virus type 1 isolate is unresponsive to the TNF-alpha synthesis inhibitor RP 55778. Le Naour, R., Clayette, P., Henin, Y., Mabondzo, A., Raoul, H., Bousseau, A., Dormont, D. J. Gen. Virol. (1994) [Pubmed]
  3. Intravenous injections of PAF-acether induce platelet aggregation in rats. Martins, M.A., Martins, P.M., Faria Neto, H.C., Bozza, P.T., Dias, P.M., Cordeiro, R.S., Vargaftig, B.B. Eur. J. Pharmacol. (1988) [Pubmed]
  4. A PAF-acether antagonist (N 48740 RP/Rhône-Poulenc) and laser-induced thrombi in rat mesenteric vessels. Weichert, W., Breddin, H.K. Haemostasis (1989) [Pubmed]
  5. RP 55778, a PAF receptor antagonist, prevents and reverses LPS-induced hemoconcentration and TNF release. Floch, A., Bousseau, A., Hetier, E., Floc'h, F., Bost, P.E., Cavero, I. Journal of lipid mediators. (1989) [Pubmed]
  6. Human endothelial cells are target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures. Bussolino, F., Camussi, G., Aglietta, M., Braquet, P., Bosia, A., Pescarmona, G., Sanavio, F., D'Urso, N., Marchisio, P.C. J. Immunol. (1987) [Pubmed]
  7. Effects of RP 55778, a tumor necrosis factor alpha synthesis inhibitor, on antiviral activity of dideoxynucleosides. Clayette, P., Dereuddre-Bosquet, N., Martin, M., Fretier, P., Dormont, D. Antimicrob. Agents Chemother. (1997) [Pubmed]
  8. Prolonged survival of renal transplants in nonimmunized and hyperimmunized rats receiving a platelet-activating factor antagonist. Freiche, J.C., Lang, J., Sedivy, P., Touraine, J.L. Transplantation (1990) [Pubmed]
  9. Platelet mobilization induced by PAF and its role in the thrombocytosis triggered by adrenaline in rats. Castro-Faria-Neto, H.C., Bozza, P.T., Martins, M.A., Dias, P.M., Silva, P.M., Cordeiro, R.S. Thromb. Haemost. (1989) [Pubmed]
  10. Inhibition of ex-vivo PAF-induced platelet aggregation by the PAF-antagonist RP 48740: relationship to plasma concentrations in healthy volunteers. Pinquier, J.L., Sedivy, P., Bruno, R., Bompart, F., Gregoire, J., Strauch, G., Gaillot, J., Clucas, A. Eur. J. Clin. Pharmacol. (1991) [Pubmed]
  11. 48740 RP, an antagonist of PAF, does not affect human plasma fibrinolysis before and after venous occlusion. Hanss, M., Dechavanne, M. Thromb. Res. (1988) [Pubmed]
  12. Modulation of pulmonary inflammation after endotoxin inhalation with a platelet-activating factor antagonist (48740 RP). Rylander, R., Beijer, L., Lantz, R.C., Burrell, R., Sedivy, P. Int. Arch. Allergy Appl. Immunol. (1988) [Pubmed]
  13. Treatment of human monocyte-derived macrophages with a TNF alpha synthesis inhibitor prior to HIV1 infection: consequences on cytokine production and viral replication. Le Naour, R., Raoul, H., Mabondzo, A., Henin, Y., Bousseau, A., Dormont, D. Res. Virol. (1994) [Pubmed]
 
WikiGenes - Universities